A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...

Sotatercept significantly reduced the risk of all-cause mortality, lung transplantation, or ≥24-hour hospitalization for ...

Pulmonary hypertension (PH) is a rare, progressive, debilitating condition characterised by elevated pulmonary artery ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease.

Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions ...

The US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog designed to enhance exercise capacity in adults with pulmonary ...

TPIP trial exceeds expectations; Phase 3 studies to begin by early 2026 Shares in Insmed Incorporated (NASDAQ:INSM) closed 28 ...

In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, ...

The pulmonary arterial hypertension treatment market has witnessed a significant transformation in recent years, driven by advancements in medical research and increasing awareness about rare ...